Back to news

Eye-Light FAQs

 

 

Q1:

Are there any   long-term data available for the effect of the treatment? Dr. Jennifer P   Craig writes: “Further evaluation of IPL for Meibomian Gland Dysfunction   (MGD) is required to determine the optimal treatment regime, and to better   understand its mechanism of action, which individuals have the greatest   potential to benefit, and the duration of the effect of IPL as a therapy for   MGD.”

A1:

IPL used in the treatment of dry eye is a relatively   “young” approach. As of 2005 there are American studies on this further   application of IPL technology and, as of today, there are thousands of   patient treated for the pathology of dry eye.

Q2:

You recommend four   applications in total even in cases of severe MGD. Dr. Toyos et al. talk   about many more treatments: “Primary outcomes included change in tear breakup   time, self-reported patient satisfaction, and adverse events.   Physician-judged improvement in dry eye tear breakup time was found for 68 of   78 patients (87%) with seven treatment visits and four maintenance visits on   average (medians), and 93% of patients reported post-treatment satisfaction   with degree of dry eye syndrome symptoms.”

A2:

In addition to the observations made by Dr. Rolando Toyos as well as Dr. Jennifer P. Craig, we can say that IPL is a great   leap forward in the treatment of this pathology, but it is not complete   because the treatment remains an indirect one that covers only the lower   eyelid area. Eye-Light® covers all benefits of using IPL, but mainly thanks to   the second technology – Light Modulation® – can treat directly the upper and   lower eyelids and this is why results are more important, faster and why   fewer applications are needed. Our Ophthalmologists can appreciate   immediately after the treatment the effect obtained. Please see Prof.   Buratto’s image report before and after one treatment only.

 

                                                                     

 

    

 

Before Treatment:

45.6 % loss area

 

After Treatment:

28.3 % loss area

Q3:

Is Eye-Light®   CE-approved for ophthalmic use in general or for MGD treatment in particular?

A3:

Eye-Light® device has the CE0476 medical mark for   the treatment of MGD with both OPE®/IPL and LIGHT MODULATION®/LLLT.   Furthermore, the device has the CE0476 medical mark for use in Dermatology /   Aesthetic Medicine. Moreover the device, and consequently both technologies,   are FDA 510(k) approved since 2010 for dermatology treatments and currently   the process to extend the treatment to eyelids applications is ongoing.

Q4:

Dr. Jennifer P. Craig who made a well-made double-blind, double-masked study for the   competitor E-Eye, says “However, evidence of the success of this treatment   modality to date has been largely anecdotal, arising from retrospective,   open-label evaluations, and no randomized controlled, investigator-masked   studies are yet available (Vegunta S, et al. IOVS 2014;55:ARVO E-Abstract   2018).” Her study was well-made.

A4:

We strongly remark the great difference and unique   features of our equipment that completes and resolves those open issues that   both surgeons above mentioned rightly indicate as “still open issues”. In   summary, thanks to the two technologies that work in synergy, for the first   time, we are able to treat the dry eye pathology in its global extent. We   like to remind that OPE® as well as Light Modulation® are covered by several   International Patents that belong to Espansione Group.

Q5:

Is there any   evidence of a potentiating effect with the Eye-Light® treatment: the more   treatments you do, the better and longer effect you will have?

A5:

The evidence of results using the combination of   both technologies applied in synergy by Eye-Light®, is highlighted by the   important immediate response after the first treatment objectively –   before/after meibography with Antares by CSO – as well as subjectively by the   patient directly that reports an immediate improvement on symptoms. The   efficacy of the two technologies applied brings also to a reduction on the   number of treatments necessary to achieve a complete result.

Q6:

How do you   recommend using the Eye-Light® on different skin types (Fitzpatrick scale)?

A6:

Eye-Light® integrates a real computer that thanks to   a management software (property of Espansione Group) calculates optimal power   of emission and length of each impulse of OPE®/IPL. There are no requirements   of adjustments nor calculations of any kind made by the operator: a sensor   “measures” the skin color allowing therefore an optimal application for any   skin type (Fitzpatrick skin scale 1-6).

Q7:

Who are allowed or   certified to use an Eye-Light®? Doctors, Ophthalmologists, Opticians, Nurses?

A7:

The unit can be used by Ophthalmologists, Doctors   and Optometrists in those countries where the latter are allowed to treat   patients.

Q8:

Do you recommend to   manually probe or squeeze the Meibomian glands after an Eye-Light® treatment?

A8:

The synergy of the two technologies does not require   further mechanical / invasive treatments.

Q9:

How is training   made?

A9:

We foresee different types of trainings:

  1. 1.      For the Distributor:

A)                   Technical training -2 hours circa

B)                   Commercial training - 4 hours circa

C)                    Hands-on training - 1 hour circa

  1. 2.      For the Customer:

A)                   Hands-on training - 2 hours circa

Q10:

How do you clean   the Eye-Light® probe after a patient has gone through the OPE®/IPL phase?

A10:

With cleansing disinfectant towels (Bactisan product   Medical Mark CE0546) we wipe clean the crystal that enters in contact with   the skin and with the same product wipe we clean/disinfect the inner side of   the Light Modulation® terminal (the mask). All of this in matter of seconds   and few Euro cents cost. All IPL units - except Eye-Light® - must be used   applying gel in large quantities to avoid risks of burns on the patient’s   face; they require an immediate and accurate cleaning of the complete   anterior part of the IPL handpiece and also of the periocular treated area.

Q11:

What is the skin   cream type used after 15 minutes Light Modulation® phase? Standard or special   eye cream or skin cream?

A11:

The product used after Light Modulation® / LLLT is a   cosmeceutical formulated by Espansione Group and is part of the proprietary   ByCure cosmeceutical line. The product, packaged in monodose vials, is   specifically            formulated to   hydrate in depth the periocular skin to re-balance the physiological skin   hydration after the treatment thermal impact.

Q12:

Can you explain why   Eye-Light does not need contact gel Vs the competitor versions from E-Eye   E-Swin, Lumenis M22, Dermamed Quadra Q4 and what are the benefits of having   no gel for the treatment/patient?

A12:

For all IPLs the use of protective gel is   compulsory, applied in a quite precise manner – minimum layer thickness 1cm /   maximum layer thickness 2cm - to avoid skin burns. Thanks to the   International Patent owned by Espansione Group, the Eye-Light® IPL terminal   is cooled by means of a circle of forced air and the temperature is   constantly controlled by an inner sensor that monitors the levels.   Furthermore, the management software calculates the exact power to be emitted   avoiding any risk of overexposure. The gel determines an instability of the   thermal emission resulting in an inaccurate impact: too much gel? Too little   gel? Do I press harder on hand piece? Additionally, application and removal   of gel are laborious and unwelcomed maneuvers by the Doctor and unpleasant   for the patient. Moreover, it represents an extra cost (€ 1.0 – 1.5) per   treatment, in addition to the time required for the application and removal.

         

 Back to Eye-Light information pages